Orchid Pharma Share News - Latest Updates, Live News & More

Latest news about Orchid Pharma

Orchid Pharma Q2 FY26: Revenue Declines 13% YoY Amid Antibiotics Market Downturn, Enmetazobactam Acquisition Completed Nov 17, 2025

Orchid Pharma faced a tough Q2 FY26 amid global antibiotics industry downturn. Revenue dropped 13% YoY to INR 194.00 crores, with net loss of INR 5.70 crores. The company completed acquisition of global rights to Enmetazobactam, expecting EU price approvals soon. Despite challenges, Orchid focuses on strategic moves including the 7ACA and Cefiderocol projects, and expansion of its Antimicrobial Stewardship Division. The company's domestic brand Orblicef shows strong performance, exceeding one-year target.

Orchid Pharma Reports Progress and Delays in QIP-Funded Projects Nov 13, 2025

Orchid Pharma Targets 13% Revenue Growth with Capacity Expansion and New Product Launches Nov 11, 2025

Orchid Pharma Reports 12% Revenue Growth in Q2, Completes Strategic Acquisitions Nov 11, 2025

Orchid Pharma Finalizes Acquisition of Allecra Therapeutics Assets Oct 30, 2025

More news about Orchid Pharma

05Sept 25

Orchid Pharma Approves Rs. 504 Crore Fundraising Plan via Equity Share Issuance

Orchid Pharma's Board of Directors has approved a plan to raise up to Rs. 504 crores through equity share issuance via preferential allotment or private placement. The fundraising aims to meet minimum public shareholding requirements as per Rule 19A(5) of the Securities Contracts (Regulation) Rules, 1957. The plan is flexible, allowing for single or multiple tranches. Shareholder approval and regulatory clearances are required before proceeding with the share issuance.

14Aug 25

Orchid Pharma Acquires Global Rights to Enmetazobactam, Reports Q1 Revenue Decline

Orchid Pharma has acquired global rights to Enmetazobactam and the trademark Exblifep from Allecra, pending completion within three months. The company reported Q1 sales of ₹173.00 crores, a 29% decrease from the previous year, with gross margins at 42% and operational EBITDA at ₹14.00 crores. The decline is attributed to a global slowdown in the antibiotics market, with both prices and volumes under pressure. Despite challenges, Orchid is progressing on strategic initiatives including domestic brand Orblicef, expanding its Antimicrobial Stewardship division, and advancing projects like 7ACA and Cefiderocol.

12Aug 25

Orchid Pharma Reports Mixed Q1 Results, Implements Cost-Cutting Measures

Orchid Pharma reported a decline in Q1 FY24 revenue to ₹172.93 crore from ₹244.41 crore in Q1 FY23, with profit after tax falling to ₹14.91 crore from ₹29.35 crore. The company announced strategic cost-reduction initiatives to improve profit margins amid challenging market conditions. These include leveraging its API portfolio, exploring export opportunities, and enhancing operational efficiency. Orchid Pharma is also progressing on two major capital expenditure projects: a new manufacturing facility in Jammu and an API facility expansion in Alathur, Tamil Nadu.

12Aug 25

Orchid Pharma Reports Q1 Results: Profit Dips Amid Revenue Decline

Orchid Pharma announced Q1 financial results showing a decline in performance. Standalone profit decreased 37.5% to Rs 1,819.74 lakhs, with net sales down 29.2% to Rs 17,292.88 lakhs. Consolidated profit fell 49.2% to Rs 1,491.06 lakhs. The company appointed internal, cost, and secretarial auditors to strengthen governance. Annual General Meeting scheduled for September 20, with e-voting starting September 17.

05Aug 25

Orchid Pharma Secures French Court Approval for Allecra Therapeutics Asset Acquisition

Orchid Pharma has received approval from a French court to acquire the assets of Allecra Therapeutics SAS, effective August 1. This follows the company's July 30 announcement of the asset purchase. Orchid Pharma disclosed this information to stock exchanges on August 5. Additionally, the company has scheduled a Board meeting for August 12 to review Q1 financial results and has implemented a trading window closure from July 1 until 48 hours after the Q1 results declaration.

31Jul 25

Orchid Pharma Shares Surge as Company Reclaims Global Rights to Novel Antibiotic

Orchid Pharma's shares hit the upper circuit, rising 5% to ₹740.10, following the company's acquisition of 100% global ownership of Enmetazobactam, a novel antibiotic. The company executed agreements to purchase assets from Allecra Therapeutics in Germany and France, including intellectual property and trademarks. Enmetazobactam, approved by EMA and FDA, has an estimated global peak sales potential of $150-200 million. Orchid Pharma also acquired a German company, renamed Orchid Pharma Europe GmbH, to expand into European markets.

30Jul 25

Orchid Pharma Secures Global Rights to Enmetazobactam Through Strategic Asset Acquisitions

Orchid Pharma has acquired assets from Allecra Therapeutics in Germany and France, securing 100% global ownership of Enmetazobactam, a novel antibiotic. The company also established Orchid Pharma Europe GmbH as a wholly-owned subsidiary in Germany. These strategic moves consolidate Orchid Pharma's control over the antibiotic, known as EXBLIFEP internationally and Orblicef in India, marking the full repatriation of the first novel antibiotic discovered in India back to its home country.

30Jul 25

Orchid Pharma Expands European Presence with German Subsidiary Acquisition

Orchid Pharma Limited has made two strategic moves to strengthen its position in the European market. The company acquired a German subsidiary, now renamed Orchid Pharma Europe GmbH, for €28,500. Additionally, Orchid Pharma is in the process of acquiring all assets related to Enmetazobactam, a novel antibiotic molecule, from Allecra Therapeutics in Germany and France. These acquisitions aim to enhance Orchid Pharma's global footprint, expand its product portfolio, and consolidate ownership of a key antibiotic developed in India.

17Jul 25

Orchid Pharma Secures ₹1,425 Crore Funding from HDFC Bank for Cefiderocol Project

Orchid Pharma Limited has entered into an agreement with HDFC Bank Limited for credit facilities totaling ₹1,425.00 crore. The funding is specifically allocated for setting up the Cefiderocol project, which involves a novel siderophore cephalosporin antibiotic. The company executed a Deed of Hypothecation with HDFC Bank to secure the credit facilities. This development has been reported to stock exchanges in compliance with SEBI regulations.

06Jun 25

NCLT Ruling on Orchid Pharma-DBS Bank Dispute: Potential Financial Implications Loom

The National Company Law Tribunal (NCLT) has issued a ruling in the legal dispute between Orchid Pharma Limited and DBS Bank. While specific details are undisclosed, the ruling is expected to significantly impact Orchid Pharma's financial landscape. Orchid Pharma's recent financial metrics show improvements, with total assets up 26.89%, total equity increased by 66.43%, and current assets growing by 58.42% year-over-year. Both current and non-current liabilities have decreased. The company's strengthened financial position may help mitigate potential adverse effects from the ruling.

29May 25

Orchid Pharma Receives USFDA's EIR with VAI Status

Orchid Pharma has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA). This follows the USFDA's acceptance of Orchid Pharma's response to previous inspection observations. The VAI status indicates that while minor issues were found, they don't require significant regulatory action. This outcome is viewed positively in the pharmaceutical industry, suggesting that Orchid Pharma has adequately addressed the USFDA's concerns and can continue operations without major regulatory hurdles in the U.S. market.

27May 25

Orchid Pharma Reports Q4 Revenue Growth Amid EBITDA Margin Pressure

Orchid Pharma's Q4 results show a 9.40% YoY revenue increase to Rs 2,375.00 million, with 9.30% QoQ growth. EBITDA declined 3.20% YoY but rose 6.10% QoQ to Rs 280.00 million. EBITDA margin decreased to 11.80%, down 154 bps YoY and 35 bps QoQ, indicating profitability challenges despite revenue growth.

26May 25

Orchid Pharma Reports Q4 Revenue Growth and Improved EBITDA, Despite Profit Dip

Orchid Pharma's Q4 results show revenue growth of 9.22% YoY to ₹2,370.00 million and improved EBITDA of ₹343.30 million. However, net profit declined 16.11% YoY to ₹278.50 million. The company saw a sequential profit improvement of 16.53% from Q3.

09Apr 25

Orchid Pharma Settles Dispute with DBS India Bank for ₹7.62 Crore

Orchid Pharma has resolved a long-standing dispute with DBS Bank India Limited through a Joint Memorandum of Compromise. The settlement, worth ₹7.62 crore, covers lease rentals for a property in Tamil Nadu from April 2020 to December 2024. The agreement includes closing pending NCLT cases, preventing future legal actions by DBS Bank, and establishing a new lease agreement for the property. This resolution allows Orchid Pharma to eliminate uncertainty, potentially reduce legal expenses, and secure continued access to the property.

20Feb 25

Orchid Pharma's Alathur API Facility Aces USFDA Inspection, Retains Exclusive Status

Orchid Pharma's API facility in Alathur, Tamil Nadu, successfully passed a surprise USFDA inspection with minor observations, maintaining its status as India's only USFDA-approved facility for Sterile Cephalosporins. The facility also renewed its EU GMP certificate, reinforcing its global market position in antibiotic manufacturing. These achievements validate the company's compliance with international regulatory standards and strengthen its ability to supply high-quality APIs to global markets.